February 24th, 2021

A full text version of this article is available.
To access article obtain online access here or login
FSH Receptor Binding Inhibitor Attenuates Ovarian Carcinogenesis by Depressing c-Myc and K-Ras Levels in Ovine Ovaries
Authors:  Zhuandi Gong, M.S., Yuhui Niu, M.S., Zhaofang Yuan, M.S., Xiaoqiang Bai, M.D., and Suocheng Wei, Ph.D.
  OBJECTIVE: To explore the follicle-stimulating hormone (FSH) receptor binding inhibitor (FRBI) effects on the levels of c-Myc and K-Ras related to ovarian cancer and to assess the mRNA and protein levels of FSH receptor (FSHR) in the cumulus-oocyte complexes (COCs) in the presence of FSH.

STUDY DESIGN: COCs were cultured for 24 hours in the in vitro maturation (IVM) media replenished with 0, 10, 20, 30, and 40 μg/mL FRBI. The contents of c-Myc and K-Ras, cAMP, and inositol trisphosphate (IP3) in IVM media were detected with ELISA kits, respectively.

RESULTS: The c-Myc contents of 4 FRBI+FSH treated groups (COM groups) were less than those of the control and FSH groups at 24 hours. The c-Myc content of the COM-3 group was lower than that of the FSH group (p<0.05). K-Ras and IP3 contents of the COM-4 group were lower than those of the FSH group (p<0.05). Expression levels of FSHR mRNAs and proteins of the COM-4 group were significantly decreased.

CONCLUSION: This study revealed that the expression levels of FSHR mRNAs and proteins of the COM-4 group were significantly decreased. FRBI treatment could decrease c-Myc and K-Ras levels in the IVM medium fluids and depress the FSHR levels of COCs. FRBI exerted its action via the signal pathway of IP3 and cAMP.
Keywords:  biomarkers, tumor; c-Myc proteins; FSH receptor binding inhibitor; FSH receptors; K-ras genes; oocyte; ovarian cancer; signal pathway
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from